| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b10e34082e0814a09ee58c52c4896cab |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-079
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-30 |
| filingDate |
2019-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6eb270f5cc83a7bfbde8d5c4c780364
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42e3b165a774f694a16580af899aafdc |
| publicationDate |
2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10676716-B2 |
| titleOfInvention |
Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same |
| abstract |
Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2 + progenitors, and then to O4 + OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, O4 + OPCs are able to differentiate into MBP + mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11603518-B2 |
| priorityDate |
2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |